uniQure (NASDAQ:QURE) Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of uniQure (NASDAQ:QURE) from a hold rating to a sell rating in a research note released on Saturday.

Several other research analysts have also recently issued reports on the stock. Mizuho raised their target price on shares of uniQure from $35.00 to $68.00 and gave the stock an “outperform” rating in a report on Thursday, June 25th. Royal Bank Of Canada upped their price target on shares of uniQure from $35.00 to $65.00 and gave the company an “outperform” rating in a report on Thursday, June 18th. The Goldman Sachs Group increased their price target on uniQure from $14.00 to $46.00 and gave the stock a “neutral” rating in a research report on Thursday, June 18th. Leerink Partners boosted their price objective on uniQure from $36.00 to $70.00 and gave the company an “outperform” rating in a report on Thursday, June 18th. Finally, Wolfe Research raised uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 target price on the stock in a report on Wednesday, July 29th. Thirteen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, uniQure has an average rating of “Moderate Buy” and a consensus price target of $65.00.

uniQure Stock Up 1.0%

Shares of QURE stock opened at $44.06 on Friday. uniQure has a fifty-two week low of $8.73 and a fifty-two week high of $71.50. The stock’s 50-day simple moving average is $37.89 and its 200-day simple moving average is $26.43. The company has a debt-to-equity ratio of 0.15, a quick ratio of 10.01 and a current ratio of 10.01. The firm has a market capitalization of $3.06 billion, a PE ratio of -10.99 and a beta of 0.93.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.40). The business had revenue of $5.84 million for the quarter, compared to analyst estimates of $5.45 million. uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. During the same quarter in the previous year, the firm posted ($0.69) earnings per share. Equities analysts expect that uniQure will post -3.74 earnings per share for the current year.

Insider Transactions at uniQure

In related news, insider Walid Abi-Saab sold 45,000 shares of the company’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $25.06, for a total value of $1,127,700.00. Following the completion of the transaction, the insider owned 169,669 shares of the company’s stock, valued at approximately $4,251,905.14. This represents a 20.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kylie O’keefe sold 15,936 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $27.06, for a total value of $431,228.16. Following the completion of the sale, the insider directly owned 108,864 shares in the company, valued at approximately $2,945,859.84. The trade was a 12.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 433,229 shares of company stock worth $17,944,799 over the last quarter. Company insiders own 4.65% of the company’s stock.

Hedge Funds Weigh In On uniQure

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Woodline Partners LP raised its position in shares of uniQure by 25.0% during the 1st quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock worth $1,864,000 after purchasing an additional 35,175 shares during the last quarter. Legal & General Group Plc purchased a new stake in uniQure during the 2nd quarter worth approximately $497,000. Marshall Wace LLP raised its holdings in shares of uniQure by 276.5% during the second quarter. Marshall Wace LLP now owns 222,979 shares of the biotechnology company’s stock valued at $3,108,000 after acquiring an additional 163,749 shares during the last quarter. California State Teachers Retirement System purchased a new position in shares of uniQure in the second quarter valued at approximately $540,000. Finally, Ameriprise Financial Inc. boosted its stake in shares of uniQure by 38.6% in the second quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company’s stock worth $10,622,000 after acquiring an additional 212,218 shares during the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.